Effects of macitentan and selexipag across prognostic age groups in patients with pulmonary arterial hypertension

BACKGROUND: Age affects disease severity and patient outcomes in pulmonary arterial hypertension. This post-hoc analysis identified prognostic age groups and associated macitentan/selexipag treatment effects. METHODS: Randomized trials evaluated macitentan (SERAPHIN; NCT00660179) and selexipag (GRIP...

Full description

Bibliographic Details

Published in:	JHLT Open
Main Authors:	Richard Channick, MD, Sarah Medrek, MD, Marion Delcroix, MD, Sean Gaine, MD, Pavel Jansa, MD, PhD, Irene Lang, MD, Vallerie McLaughlin, MD, Sanjay Mehta, MD, Tomas Pulido, MD, Bhagavatula Sastry, MD, Rogerio Souza, MD, PhD, Adam Torbicki, MD, Carol Zhao, MS, Paul Strachan, MD, Peter Agron, PhD, Joseph Yen, PhD, Olivier Sitbon, MD, PhD
Format:	Article
Language:	English
Published:	Elsevier 2025-02-01
Subjects:	Pulmonary arterial hypertension SERAPHIN GRIPHON Selexipag Macitentan
Online Access:	http://www.sciencedirect.com/science/article/pii/S2950133424001472